An intensive nurse-led, multi-interventional clinic is more successful in achieving vascular risk reduction targets than standard diabetes care

Irish Journal of Medical Science

Volumn 178, Issue 2, 2009, Pages 179-186

  MacMahon Tone, Jacqueline ^a   Agha, A ^a   Sherlock, M ^a   Finucane, F ^a   Tormey, W ^a   Thompson, Chris J ^a  

^a BEAUMONT HOSPITAL   (Ireland)

Author keywords

Nurse led; Type 2 diabetes; Vascular risk reduction

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; ORAL ANTIDIABETIC AGENT; PERINDOPRIL; SULFONYLUREA; TRIACYLGLYCEROL; WARFARIN;

ADULT; ANKLE EDEMA; ARTICLE; BODY MASS; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIASTOLIC BLOOD PRESSURE; DIET THERAPY; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOGLYCEMIA; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MYOSITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NURSING INTERVENTION; OPEN STUDY; OPTIMAL DRUG DOSE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; SMOKING; STOMACH DISEASE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; HEALTH STATUS INDICATOR; INTERVENTION STUDY; IRELAND; MIDDLE AGED; NURSING; PROSPECTIVE STUDY; RISK ASSESSMENT;

CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; HEALTH STATUS INDICATORS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INTERVENTION STUDIES; IRELAND; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; RISK REDUCTION BEHAVIOR;

EID: 67649543739     PISSN: 00211265     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11845-009-0316-6     Document Type: Article

References (50)

1. International Diabetes Foundation (2003) Diabetes atlas, 2nd edn Executive summary. International Diabetes Foundation, Brussels, p 8
2. World Health Organisation (2007) Prevalence of diabetes in the WHO European region. http://www.who.int/diabetes/facts/world_figures/en/ index4.htm. Accessed 21 Nov 2007
3. Institute of Public Health in Ireland (2006) Making diabetes count, a systematic approach to estimating population prevalence on the island of Ireland in 2005. First report of the Irish Diabetes Prevalence Working Group, Ireland and Northern Ireland's Population Health Observatory (INIsPHO), Dublin
4. Campbell IW (2001) Type 2 diabetes mellitus, 'the silent killer'. Pract Diabetes Int 18(6):187-191. doi: 10.1002/pdi.230
5. Feher MD (2004) Diabetes: Preventing coronary heart disease in a high risk group. Heart 90(Suppl 4):iV18-iv21. doi: 10.1136/hrt.2004.037572
6. Laakso M (1999) Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 48:937-942. doi: 10.2337/diabetes.48.5.937
7. Curb JD, Pressel SL, Cutler JA, For the Systolic Hypertension in the Elderly Program Cooperative Research Group (SHEP) et al (1996) Effect of diuretic-based anti-hypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 276:1886-1892. doi: 10.1001/jama.276.23.1886
8. Staessen JA, Fagard R, Thijs L et al (1997) Morbidity and mortality in the placebo controlled European trial of isolated systolic hypertension (Syst-Eur) in the elderly. Lancet 350:757-764. doi: 10.1016/ S0140-6736(97)05381-6
9. Hansson L, Zanchetti A, Carruthers SG et al (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the hypertension optimal treatment (HOT) randomised trial. HOT Study Group. Lancet 351:1755-1762. doi: 10.1016/S0140-6736(98)04311-6
10. UK Prospective Diabetes Study Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ 317:703-713
11. UK Prospective Diabetes Study Group (1998) Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 39). BMJ 317:713-720
12. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) Major outcomes in high-risk hypertensive patients randomised to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic: The anti-hypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 288:2981-2997. doi: 10.1001/jama.288.23.2981
13. Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-1389
14. Shepherd J, Cobbe SM, Ford I, West of Scotland Coronary Prevention Study Group (WOSCOPS) et al (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333:1301-1307. doi: 10.1056/NEJM199511163332001
15. Sacks FR, Pfeffer MA, Moye LA, Cholesterol and Recurrent Events Trial Investigators (CARE) et al (1996) The effect of Pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335:1001-1009. doi: 10.1056/NEJM199610033351401
16. Heart Protection Study Collaborative Group (2002) MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 360:7-22. doi: 10.1016/S0140-6736(02)09327-3
17. Sever PD, Dahlof B, Poulter NR et al (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian cardiac outcomes trial-lipid lowering arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 361:977-986. doi: 10.1016/S0140-6736(03)12837-1
18. Colhoun HM, Betteridge DJ, Durrington PN, CARDS Investigators et al (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet 364:685-696. doi: 10.1016/S0140-6736(04)16895-5
19. Beckman JA, Creager MA, Libby P (2002) Diabetes and atherosclerosis: epidemiology, pathophysiology and management. JAMA 287:2570-2581. doi: 10.1001/jama.287.19.2570
20. Campos C (2007) Treating the whole patient for optimal management of type 2 diabetes: Considerations for insulin therapy. South Med J 100(8):804-811
21. Gaede P, Vedel P, Larsen N et al (2003) Multifactorial Intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383-393. doi: 10.1056/NEJMoa021778
22. American Diabetes Association (2007) Standards of medical care in diabetes. Diabetes Care 30(Suppl. 1):S4-S41. doi: 10.2337/dc07-S004
23. Borzecki AM, Wong AT, Hickey EC et al (2003) Hypertension control; how well are we doing? Arch Intern Med 163:2705-2711. doi: 10.1001/ archinte.163.22.2705
24. Berlowitz DR, Ash AS, Hickey EC et al (1998) Inadequate management of blood pressure in a hypertensive population. N Engl J Med 339:1957-1963. doi: 10.1056/NEJM199812313392701
25. Berlowitz DR, Ash AS, Hickey EC et al (2003) Hypertension management in patients with diabetes; the need for more aggressive therapy. Diabetes Care 26:355-359. doi: 10.2337/diacare.26.2.355
26. Sherlock M, Mylotte D, Mac Mahon J et al (2006) Lipid lowering targets are easier to attain than those for treatment of hypertension. Ir J Med Sci 175(4):36-41
27. Smith S, Bury G, O'Leary M, Shannon W, Tynan A, Staines A, Thompson C (2004) The North Dublin randomized controlled trial of structured diabetes shared care. Fam Pract 21:39-45. doi: 10.1093/fampra/cmh109
28. Winocour PH (2002) Effective diabetes care: A need for realistic targets. BMJ 324:1577-1580. doi: 10.1136/bmj.324.7353.1577
29. Denver EA, Barnard M, Woolfson RG, Earle KA (2003) Management of uncontrolled hypertension in a nurse-led clinic compared with conventional care for patients with type 2 diabetes. Diabetes Care 26:2256-2260. doi: 10.2337/diacare.26.8.2256
30. New JP, Mason JM, Freemantle N et al (2003) Specialist nurse-led intervention to treat and control hypertension and hyperlipidaemia in diabetes (SPLINT). Diabetes Care 26:2250-2255. doi: 10.2337/ diacare.26.8.2250
31. American Diabetes Association, Position Statement (2001) Standards of medical care for patients with diabetes mellitus. Diabetes Care 24(Supp 1):S33-S43. doi: 10.2337/diacare.24.1.33
32. American Diabetes Association (2002) Standards of medical care for patients with diabetes mellitus. Diabetes Care 25(supp 1):S33-S49. doi: 10.2337/diacare.25.2007.S33
33. American Diabetes Association (1997) Aspirin therapy in diabetes (position statement). Diabetes Care 20:1772-1773
34. American Diabetes Association (2002) Management of dyslipidaemia in adults with diabetes (position statement). Diabetes Care 25:S74-S77. doi: 10.2337/diacare.25.2007.S74
35. Nathan DM (2002) Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med 347(17):1342-1349. doi: 10.1056/NEJMcp021106
36. LeRoith D, Smith DO (2005) Monitoring glycaemic control, the cornerstone of diabetes care. Clin Ther 27:1489-1499. doi: 10.1016/ j.clinthera.2005.10.010
37. Nathan DM, Buse JB, Davidson MB et al (2006) Management of hyperglycaemia in type 2 diabetes, a consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29(8):1963-1972. doi: 10.2337/dc06-9912
38. Nolan JJ, O'Halloran D, McKenna TJ et al (2006) The cost of treating type 2 diabetes (CODEIRE). Ir Med J 99(10):307-310
39. Fontbonne A, Eschwege E, Cambien F et al (1989) Hypertriglyceridaemia as a risk factor of coronary heart disease; mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study. Diabetologia 32:300-304. doi: 10.1007/BF00265546
40. Gaede P, Vedel P, Parving HH, Pedersen O (1999) Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria. Lancet 353:617-622. doi: 10.1016/ S0140-6736(98)07368-1
41. Colhoun HM, Dong W, Poulter NR (1998) Blood pressure screening, management and control in England: Results from the health survey for England 1994. J Hypertens 16:747-752. doi: 10.1097/ 00004872-199816060-00005
42. Chobanian AV, Bakris GL, Black HR, National High Blood Pressure Education Program Coordinating Committee et al (2003) The seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. JAMA 289:2560-2571. doi: 10.1001/ jama.289.19.2560
43. Lewington S, Clarke R, Qizilbash N et al (2002) Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360:1903-1913. doi: 10.1016/S0140-6736(02)11911-8
44. Larme AC, Pugh JA (2001) Evidence-based guidelines meet the real world. Diabetes Care 24:1728-1733. doi: 10.2337/diacare.24.10.1728
45. Kaplan NM (2001) Management of hypertension in patients with type 2 diabetes mellitus: Guidelines based on current evidence. Ann Intern Med 135:1079-1083
46. IDF Clinical Guidelines Task Force (2005) Global guideline for type 2 diabetes. International Diabetes Federation, Brussels, pp 35-38
47. Taylor CB, Miller NH, Reilly KR et al (2003) Evaluation of a nurse-care management system to improve outcomes in patients with complicated diabetes. Diabetes Care 26:1058-1062. doi: 10.2337/diacare.26.4.1058
48. The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986. doi: 10.1056/NEJM199309303291401
49. The UK Prospective Diabetes Study (UKPDS) Group (1998) Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. BMJ 317:720-726
50. The UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853. doi: 10.1016/ S0140-6736(98)07019-6